MISSION: managed a pharmaceutical factory extension to double manufacturing capacity for a respiratory medical device, from 20 to 40 M units/year (65 people, €130M Capex).
ACTIONS: established program governance according to PMO (organization structure, strategy, finances, schedule, deliverables, risks and mitigation plans) - Managed stakeholders (business / finances / engineering / quality) - Member of site leadership team.
Construction of 2 new production lines (formulation + medical device assembly/packing), a new fully automated warehouse and a new Quality Control laboratory.
Managed transition to business in order to deliver assets ready to manufacture commercial batches.
ACHIEVEMENTS: transfer to business completed for the first 3 assets (assembly/packing line in February 2017, Quality Control lab in March 2018, fully automated warehouse in April 2018). Last asset (formulation line) to be transferred to business due end 2018.
Unilabs - Medical Biology laboratories, turnover €160M, 1300 employees
June 2012
to October 2014
Full-time
Paris
France
MISSION: manage the post M&A operational integration of 50 new biology diagnosis and pathology laboratories into a French existing network, ending to a total of 102 laboratories in 19 regions.
ACTIONS: Consolidated production into regional core labs while keeping proximity collecting centers and emergency hospital labs / optimized personnel and equipment / harmonized and standardized operations / Implemented lean solutions / 6 months acting as turnaround manager for the Champagne region.
ACHIEVEMENTS: built strong foundations in each regional labs to support further commercial development / Champagne region laboratories back on track in terms of organization, financial performance and quality of service / implemented €4.9M operational synergies in less than 2 years.
MISSION: built technical platforms and reorganized 3 majors medical supporting functions :
BIOLOGY: regrouped 23 medical diagnosis laboratories, biology and pathology, into one single 20.000 m² medical center building (800 people, 7000 analysis/day).
STERILIZATION: created with GCS Sterinord one of the most innovative sterilizing surgical instrument industrial platforms in France (90 people, 1000 surgical kits a day, 5 hospitals).
BLOOD TRANSFUSION: revamped the hospital blood histocompatibility and distribution processes for blood transfusion with Etablissement Français du Sang (60 people, 50.000 blood bags a year).
ACHIEVEMENTS: operational expenses decreased by €5M - improved drastically quality of service to clinicians by reducing turnaround time by half.
Redesigned the organization of a 1200 people strong retail company to take full advantage of new functionalities brought with implementation of a new ERP (SAP).
Managed the creation of a New-Zealand wine import and bottling company in China.
Assessed potential of China medical market and ways of entry for high-end medical equipment.
Gilson - Robotics and Lab Equipment, turnover $60M, 400 employees
March 2000
to February 2003
Full-time
Madison
United States - Wisconsin
Robotics Business Unit manager (turnover $16M, 30 people).
Developed and launched a new line of robots for biotech and pharmaceutical industries / coordinated engineering development between French and USA teams => $5M extra sales.
In 2002-2003, managed the consolidation of the business unit in one single location in US => decreased operating expenses by 15%.
French Atomic Energy Agency - Cis Bio International - Medical Robotics, turnover €35M, 200 employees
February 1997
to February 2000
Full-time
Saclay
France
Set up and managed customer service teams in 18 countries to support the launch of a medical diagnosis robot, with a strong focus in Asia with the creation of a hub in Japan to cover the Asia-Pacific region (60 people).
French Atomic Energy Agency - Cis Bio International - Medical Robotics, turnover €35M, 200 employees
February 1993
to January 1997
Full-time
Chicago
United States - Illinois
Managed the joint successful development of a medical diagnosis robot between a French company (Cis Bio International) and an American one (Packard) (25 people).